In a breakthrough poised to reshape cancer treatment, Houston Methodist has developed the first personalized mRNA cancer vaccine designed to prevent recurrence of osteosarcoma, a rare and aggressive type of bone cancer. This first-of-its-kind treatment was made possible through a compassionate use allowance from the U.S. Food and Drug Administration (FDA) and represents a major step in personalized medicine and cancer care.
Continue Reading this article here
